MarketFriction

Panacea Biotec Ltd

NSE PANACEABIO · BSE 531349 · Pharmaceuticals
₹359.05 -1.90%
NSE close2026-10-01
52 week range292.40 - 647.00
Market cap₹2,290 Cr.
Price band 10% Delivery 49.3%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales143.02150.50136.46115.72147.35163.49132.53166.70141.13165.19166.75199.57
Expenses146.58150.65142.50129.71140.35155.53159.41167.88158.92153.45164.18193.90
Operating Profit-3.56-0.15-6.04-13.997.007.96-26.88-1.18-17.7911.742.575.67
OPM %-2.49%-0.10%-4.43%-12.09%4.75%4.87%-20.28%-0.71%-12.61%7.11%1.54%2.84%
Other Income6.008.4613.556.547.426.3936.3016.999.105.055.266.98
Interest0.910.850.820.870.980.991.040.862.141.851.201.18
Depreciation9.319.118.818.738.688.988.428.398.348.457.887.90
Profit before tax-7.78-1.65-2.12-17.054.764.38-0.046.56-19.176.49-1.253.57
Tax %6.56%33.33%-6.13%-6.86%1.05%-1.37%4,875.00%39.63%-26.92%40.06%-20.00%38.38%
Net Profit-8.29-2.20-1.99-15.884.714.44-1.993.96-14.013.89-1.002.20
EPS in Rs-1.35-0.37-0.32-2.580.780.74-0.310.66-2.270.650.080.38
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales653544593457544625661460559559640673
Expenses541505509591484548674558579584644670
Operating Profit1123984-1346077-13-98-20-25-52
OPM %17%7%14%-29%11%12%-2.0%-21%-3.5%-4.4%-0.7%0.3%
Other Income70628338-2191,68715462553626
Interest12710110110517418518144466
Depreciation736857544346443937353333
Profit before tax-19-67-6645-178-1461,449131-8-7-10
Tax %10%-16%15%17%9%1%26%363%201%10%-3%
Net Profit-21-56-7638-194-1481,078-34-2-9-7-9
EPS in Rs-2.98-8.89-12.076.15-31.69-24.09175.91-5.42-0.19-1.37-0.88-1.16
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth0%0%12%10%
Compounded Profit Growth5%13%21%43%
Stock Price CAGR14%6%31%-8%
Return on Equity%-10%-4%-2%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital666666666666
Reserves449426350303344193-235871837836829829
Borrowings1,1111,1059949416467428203420212224
Other Liabilities364317440349379449587848407378433404
Total Liabilities1,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,262
Fixed Assets1,1441,0711,001949806657609622600582567576
CWIP15516130402324341742102128144
Investments1597756051340310
Other Assets6166147506025427035341,114615517592532
Total Assets1,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,262
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity3791131118105-30107-108-422-0-2717
Cash from Investing Activity-3716-2655-6-35-481,2834301065-40
Cash from Financing Activity-1-117-107-164-10191-47-1,176-18-3-3-1
Net Cash Flow-1-10-29-22612-2-10735-25
Free Cash Flow3085107103100-2189-119-424-71-77-37
CFO/OP96%64%320%146%-77%-36%141%-2,235%429%-12%108%-511%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days527995847146494548374742
Inventory Days404516770651173344311296292282391251
Days Payable272318607540572463440327256244413247
Cash Conversion Cycle184278259195-328-73-801483762546
Working Capital Days-12627-46-96-36393-43-229-5-26551
ROCE %0%4%2%3%-16%5%5%-6%-10%-4%-5%-2%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters73.59%73.59%73.59%73.47%72.87%72.49%72.48%72.48%72.48%72.48%72.48%72.48%
FIIs0.26%0.26%0.27%0.26%0.37%0.38%1.16%0.79%1.06%1.36%1.60%2.31%
DIIs0.57%0.69%0.84%1.07%1.16%1.16%1.49%1.52%1.80%1.85%1.96%2.25%
Public25.58%25.46%25.30%25.21%25.60%25.96%24.86%25.20%24.65%24.31%23.96%22.96%
No. of Shareholders48,87847,09146,24245,51339,98235,44633,59334,25633,59334,59732,62033,532

Fundamentals

Market Cap₹ 2,290 Cr.
Current Price₹ 375
Book Value₹ 136
ROCE-2.43 %
ROE-2.42 %
Dividend Yield0.00 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)10%
Compounded Profit Growth (TTM)43%
Consolidated figures.
Valuation
Market capRs 2,199 Cr
Enterprise valueRs 2,158 Cr
Price to book2.63x
Price to sales3.27x
EV / EBITDA75.52x
EV / sales3.21x
Price to cash flow131.77x
Earnings yield-0.32%
P/B, 3-year average2.10x
P/E, 5-year average0.84x
P/B, 5-year average1.62x
Profitability
Operating margin (excl. other income)-0.71%
Operating margin (incl. other income)4.96%
EBITDA margin4.25%
Pre-tax margin-1.54%
Net profit margin-1.06%
Net margin, latest quarter1.15%
ROE-0.64%
ROCE-0.15%
ROA-0.42%
ROE, 3-year average-0.59%
ROCE, 3-year average-0.01%
ROA, 3-year average-0.39%
ROE, 5-year average65.44%
ROCE, 5-year average43.81%
ROA, 5-year average14.01%
ROIC (approx.)-0.49%
Tax rate2.85%
Other income / net worth4.34%
Growth
Sales growth (latest year)14.43%
Sales CAGR, 3 years11.63%
Sales CAGR, 5 years0.47%
Sales growth QoQ19.68%
Profit growth QoQ342.31%
Sales growth YoY (latest quarter)19.72%
Profit growth YoY (latest quarter)-43.21%
Per share
EPS (TTM)Rs -1.16
EPS (latest year)Rs -0.88
EPS (latest quarter)Rs 0.38
EPS, 3-year averageRs -0.81
EPS, 5-year averageRs 33.64
Book value per shareRs 136.30
Sales per shareRs 109.82
Cash flow per shareRs 2.72
Free cash flow per shareRs -6.04
Efficiency
Asset turnover0.51x
Fixed asset turnover1.11x
Inventory turnover1.95x
Inventory days187 days
Debtor days42 days
Debtors turnover8.70x
Creditor days247 days
Cash conversion cycle46 days
Working capital days51 days
Leverage
Total debtRs 24 Cr
Cash and bankRs 64 Cr
Net debtRs -41 Cr
Debt to equity0.03x
Net debt / EBITDA-1.42x
Interest coverage-0.63x
Current ratio (filing 2026-03-31)1.47x
Quick ratio (filing 2026-03-31)0.92x
Trade payables (filing 2026-03-31)Rs 190 Cr
Owners' fund to total sources66.14%
Debt to assets1.87%
Cash flow
Cash from Operating Activity (latest year)Rs 17 Cr
Cash from Investing Activity (latest year)Rs -40 Cr
Cash from Financing Activity (latest year)Rs -1 Cr
Net Cash Flow (latest year)Rs -25 Cr
Free cash flow (latest year)Rs -37 Cr
FCFE (approx.: FCF + change in debt)Rs -36 Cr
Cash from ops / profit, 5 years-0.53x
Sales to cash flow38.33x
Statement figures
Net sales (TTM)Rs 673 Cr
Net sales (latest year)Rs 640 Cr
Sales (latest quarter)Rs 200 Cr
Operating profit excl. other income (latest year)Rs -5 Cr
Operating profit (latest quarter)Rs 6 Cr
Other income (TTM)Rs 26 Cr
EBITDA (TTM)Rs 29 Cr
PBDT (TTM)Rs 22 Cr
Profit before tax (TTM)Rs -10 Cr
Tax (latest year)Rs -0 Cr
Net profit (TTM)Rs -7 Cr
Net profit (latest year)Rs -5 Cr
Net profit (latest quarter)Rs 2 Cr
Depreciation (TTM)Rs 33 Cr
Depreciation (latest quarter)Rs 8 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 376 Cr
Total expenditure (latest year)Rs 644 Cr
Total income (latest year)Rs 676 Cr
Share capitalRs 6 Cr
ReservesRs 829 Cr
Shareholders' fundsRs 835 Cr
Total assetsRs 1,262 Cr
Net blockRs 576 Cr
Capital work in progressRs 144 Cr
InvestmentsRs 10 Cr
ReceivablesRs 74 Cr
InventoryRs 193 Cr
Other liabilitiesRs 404 Cr
Shares outstanding (crore)6.13
Ownership
Promoter holding72.48% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 2.63 is at the 45th percentile (median 2.74).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodPANACEABIONifty 50Difference
1 week-4.2%-2.8% -1.4 pts
1 month-8.1%-6.8% -1.4 pts
3 months-34.9%-7.6% -27.2 pts
6 months+21.3%+0.4% +20.9 pts
1 year-14.6%-9.9% -4.6 pts
2 years+15.0%-13.6% +28.6 pts
3 years+115.6%+14.2% +101.4 pts
5 years+27.5%+27.9% -0.4 pts
1 mutual fund schemes hold about ₹0 Cr. Over three months 0 bought more and 0 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Bandhan BSE Healthcare Index Fund0.04%0 -0%

Red flags

F-score 6 of 8
lookRepeated losses Net loss in each of the last two years
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹200 Cr +19.7% vs Jun 2025. Net profit ₹2 Cr -44.4%.
Against our estimate for Jun 2026: sales +5.5%, profit +32.6% in line. Our estimate for Sep 2026: sales Rs 173 Cr, profit Rs 0 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-09-19Annual General Meeting
2023-09-21Annual General Meeting
2022-09-19Annual General Meeting
2021-09-16 Annual General Meeting
2020-12-15 Annual General Meeting
2020-09-21 Demerger
2019-09-19 Annual General Meeting
2018-09-19 Annual General Meeting
2017-09-18 Annual General Meeting
2016-09-22 Annual General Meeting
2015-09-22 Annual General Meeting
2014-09-17Annual General Meeting
2013-09-17Annual General Meeting
2012-09-20Annual General Meeting
2011-09-19Annual General Meeting And Dividend Re.0.75 Per Share
2010-09-16Annual General Meeting And Dividend Re.0.25 Per Share
2009-09-18Annual General Meeting
2008-09-19Agm/Dividend - 100%
2007-09-21Agm/Dividend-100%
2006-09-22Agm/Dividend-100%
DateTypeWhat it says
2026-10-01Shareholder meetingVoting results.
2026-09-29Shareholder meetingProceedings of Annual General Meeting held on September 29, 2026
2026-09-29LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-09-26LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-09-15General UpdatesGeneral Updates
2026-09-07General UpdatesGeneral Updates - Book closure for the purpose of AGM
2026-09-07General UpdatesGeneral Updates - Confirmation on letter being sent to the concerned shareholders providing the weblink for accessing the Annual Report for financial ...
2026-09-07Shareholder meetingNotice of Annual General Meeting to be held on September 29, 2026
2026-09-07UpdatesDetails of Shares dematerialized during August 2026.
2026-08-13Board meeting outcomePanacea Biotec Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-05UpdatesDetails of Shares dematerialized during July 2026.
2026-08-05Order winBagging/Receiving of orders/contracts
2026-07-24LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-07-16LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-07-08UpdatesDetails of Shares dematerialized during June 2026.
2026-07-07LitigationPendency of Litigation(s)/dispute(s) or the outcome impacting the Company
2026-06-17Disclosure under SEBI TakeovDr. Rajesh Jain Karta of Rajesh Jain (HUF) has submitted to the Exchange a copy of Disclosures under Regulation 10(6)-Report to stock Exchange in resp...
2026-06-11Disclosure under SEBI TakeovSandeep Jain has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acqu...
2026-06-08Press ReleaseA press release dated Jun 08, 2026, titled "Launch of the DENSTAR project: advancing the licensure of a tetravalent liveattenuateddengue vaccine (Deng...
2026-06-05Disclosure under SEBI TakeovRajesh Jain has Submitted to the Exchange a copy of Disclosure under Regulation 10 (5) of the Securities and Exchange Board of India (Substantial Acqu...
2026-06-05UpdatesDetails of Shares dematerialized during May 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
2026-05-30Director changeChange in Director(s) of the company.
2026-05-30Board meeting outcomePanacea Biotec Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-05-29General UpdatesChange in directors in the Companys material wholly owned subsidiary, Panacea Biotec Pharma Limited
2026-05-07UpdatesDetails of Shares dematerialized during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2020-09-09NCLTPanacea Biotec Ltd. And Ravinder Heights Ltd. Vs :
2020-08-14NCLTPanacea Biotec Ltd. Vs Ravinder Heights Ltd.
2020-08-10NCLTPanacea Biotec Ltd. And Ravinder Heights Ltd. Vs :
2020-01-03CESTATPANACEA BIOTEC LTD ---VS.--- DELHI-III
2019-05-20CESTATPANACEA BIOTEC LTD ---VS.--- DELHI-III
2019-05-09CESTATPANACEA BIOTEC LTD ---VS.--- DELHI-III
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
EPS in the scrip is zero (4 trailing quarters)High low price variation greater than 100perc in previous 6 months

Quick answers

What is the market cap of Panacea Biotec Ltd?

Panacea Biotec Ltd (PANACEABIO) has a market capitalisation of Rs 2,290 Cr. at the 2026-10-01 close.

What were Panacea Biotec Ltd's latest quarterly results?

In the Jun 2026 quarter, Panacea Biotec Ltd sales was Rs 200 Cr (+19.7% vs Jun 2025) and net profit was Rs 2 Cr.

What is the 52-week high and low of Panacea Biotec Ltd?

The 52-week high is Rs 647.00 and the 52-week low is Rs 292.40.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03